Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study

Fig. 4

Serum biomarker relations to the longitudinal outcome. Serum biomarker levels were correlated against longitudinal PACC score values and plotted as one standard deviation (SD) above and below the mean standardized biomarker level. Available subject numbers throughout follow-ups were as follows: baseline, N = 289; Y1, 245; Y2, 213; Y3, 164; Y4, 89; Y5, 20. Correlations are displayed with confidence intervals. Results are adjusted for age, sex, BMI, and APOE status. Serum FABP-3 did not differ at baseline, but higher baseline levels predicted cognitive decline at follow-up (A, p = 0.003). In contrast, sAXL (B) did not predict change over time, but differed at baseline, with higher levels in subjects with stronger cognitive impairment (p = 0.003)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193